Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Allaire

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Liver Cancer|January 30, 2026
Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular CarcinomaGiuliana Amaddeo, Manon Allaire, Maria Stella Franzè, et al.
JHEP Reports : Innovation in Hepatology|January 1, 2025
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 studyJean-Charles Nault, Nanthara Sritharan, Gontran Verset, et al.
Hepatology International|August 25, 2025
Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort studyNingning Zhang, Kaipeng Liu, Yuexi Yu, et al.
Hepatology (Baltimore, Md.)|May 21, 2021
Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal BleedingAurélie Walter, Marika Rudler, Pol Olivas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2025
Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular CarcinomaApolline Commin, Chloé Metivier, Manon Allaire, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 17, 2024
French guidelines on TIPS: Indications and modalitiesHélène Larrue, Manon Allaire, Delphine Weil-Verhoeven, et al.
BMC Cancer|July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 20, 2026
Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive managementEleonora De Martin, Teresa Maria Antonini, Thomas Uguen, et al.
Liver Cancer|September 26, 2022
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaElia Gigante, Christian Hobeika, Brigitte Le Bail, et al.
Journal of Hepatology|February 12, 2026
Detection of Esophageal Varices and Prediction of Hepatic Decompensation in Unresectable Hepatocellular Carcinoma using AI: AI Detection of Varices and DecompensationAsier Rabasco Meneghetti, Claudia Campani, Charles Roux, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Liver Cancer|January 30, 2026
Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular CarcinomaGiuliana Amaddeo, Manon Allaire, Maria Stella Franzè, et al.
JHEP Reports : Innovation in Hepatology|January 1, 2025
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 studyJean-Charles Nault, Nanthara Sritharan, Gontran Verset, et al.
Hepatology International|August 25, 2025
Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort studyNingning Zhang, Kaipeng Liu, Yuexi Yu, et al.
Hepatology (Baltimore, Md.)|May 21, 2021
Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal BleedingAurélie Walter, Marika Rudler, Pol Olivas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2025
Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular CarcinomaApolline Commin, Chloé Metivier, Manon Allaire, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 17, 2024
French guidelines on TIPS: Indications and modalitiesHélène Larrue, Manon Allaire, Delphine Weil-Verhoeven, et al.
BMC Cancer|July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 20, 2026
Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive managementEleonora De Martin, Teresa Maria Antonini, Thomas Uguen, et al.
Liver Cancer|September 26, 2022
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaElia Gigante, Christian Hobeika, Brigitte Le Bail, et al.
Journal of Hepatology|February 12, 2026
Detection of Esophageal Varices and Prediction of Hepatic Decompensation in Unresectable Hepatocellular Carcinoma using AI: AI Detection of Varices and DecompensationAsier Rabasco Meneghetti, Claudia Campani, Charles Roux, et al.
Pageof 9